BrainCo

China's brain-computer interface sector recorded 47 funding rounds in the first half of 2026, 38 of them disclosing terms for a combined RMB 5.38 billion (approx. $750 million). A broader tally used by Chinese financial media puts the total at 64 deals and roughly RMB 7.25 billion (approx. $1 billion). Either figure is more than double the whole of 2025 (49 deals, RMB 2.72 billion) at a comparable deal count. The record lists every deal by month — company, technical approach, round, amount, investors — and identifies three structural patterns: ultrasound and non-invasive approaches moving quickly into a field long defined by implants, Big Tech and municipal state funds entering at the same time, and nearly half of all transactions still sitting at angel or seed stage.

People's Daily Online reported that BrainCo completed an RMB 2 billion Series B+ round in January 2026, the largest single BCI financing in China at the time. The report did not disclose the lead investor, a complete investor list or the post-money valuation. The round indicates a capital-intensive expansion phase across BrainCo's non-invasive and medical product lines.

BrainCo's FocusXin Medical Edition combines a single-channel prefrontal EEG device registered as 浙械注准20232071898 with ADHD rehabilitation software registered as 浙械注准20252211934. The Class II system is intended for supplementary rehabilitation training in children aged 6 to 12 with ADHD. Its defined medical use should not be generalized into approval for an unspecified consumer BCI product.